Sample Mining and Data Mining: Combined Real‐Time and Retrospective Approaches for the Identification of Emerging Novel Psychoactive Substances
暂无分享,去创建一个
[1] C. Morgan,et al. Ketamine use: a review. , 2012, Addiction.
[2] Ju‐Seop Kang. Principles and Applications of LC-MS/MS for the Quantitative Bioanalysis of Analytes in Various Biological Samples , 2012 .
[3] Alan H B Wu,et al. High-Resolution Mass Spectrometry for Untargeted Drug Screening. , 2016, Methods in molecular biology.
[4] E. Schneider,et al. Opioid activity and distribution of fentanyl metabolites , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.
[5] Aaron A. Urbas,et al. NPS Data Hub: A web-based community driven analytical data repository for new psychoactive substances , 2018, Forensic Chemistry.
[6] Y. Sarne,et al. On the opioid nature of phencyclidine and its 3-hydroxy derivative. , 1981, European journal of pharmacology.
[7] G. L. Henderson,et al. Designer drugs: past history and future prospects. , 1988, Journal of forensic sciences.
[8] Tadessa Harper-Nichols. Prescription Drug Monitoring Program. , 2014, Journal of the California Dental Association.
[9] C. Herrmann,et al. Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach , 2014, Analytical and Bioanalytical Chemistry.
[10] E. Freye. Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs , 2010 .
[11] B. Logan,et al. N-Ethyl Pentylone (Ephylone) Intoxications: Quantitative Confirmation and Metabolite Identification in Authentic Human Biological Specimens. , 2018, Journal of analytical toxicology.
[12] C. McKay,et al. Ketamine abusers presenting to the emergency department: a case series. , 2000, The Journal of emergency medicine.
[13] M. Huestis,et al. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. , 2017, Journal of analytical toxicology.
[14] J. Prasain. Tandem Mass Spectrometry - Applications and Principles , 2012 .
[15] David E. Smith,et al. The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis , 2015, Journal of psychoactive drugs.
[16] Jeri D Ropero-Miller,et al. The Opioid Epidemic: Moving Toward an Integrated, Holistic Analytical Response. , 2018, Journal of analytical toxicology.
[17] M. Tsokos,et al. A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine. , 2018, Journal of analytical toxicology.
[18] Thomas Kraemer,et al. Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with informatio , 2014, Analytical chemistry.
[19] Carla Lewandowski,et al. Information Sharing Using a State Fusion Center: A Case Study of the New Jersey Regional Operations Intelligence Center , 2012 .
[20] B. Thomas,et al. Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. , 2012, Analytical chemistry.
[21] U. Garg. Clinical Applications of Mass Spectrometry in Drug Analysis , 2016, Methods in Molecular Biology.
[22] Leonard J Paulozzi,et al. Prescription drug monitoring programs and death rates from drug overdose. , 2011, Pain medicine.
[23] Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. , 2013, Journal of analytical toxicology.
[24] R. Subramanian,et al. Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. , 2014, Analytical chemistry.
[25] R. Gerona,et al. Non-targeted screening for novel psychoactive substances among agitated emergency department patients , 2016, Clinical toxicology.
[26] N. Volkow,et al. Abuse of New Psychoactive Substances: Threats and Solutions , 2016, Neuropsychopharmacology.
[27] Herbert Oberacher,et al. Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.
[28] K. Redda,et al. Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology, and Behavior , 1989 .
[29] D. Deforce,et al. Simultaneous, quantitative determination of opiates, amphetamines, cocaine and benzoylecgonine in oral fluid by liquid chromatography quadrupole-time-of-flight mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[30] H. Maurer. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. , 2005, Clinical biochemistry.
[31] C. Kostakis,et al. A Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data. , 2018, Journal of analytical toxicology.
[32] S. Johansen,et al. Simultaneous screening and quantification of 52 common pharmaceuticals and drugs of abuse in hair using UPLC-TOF-MS. , 2010, Forensic science international.
[33] P. Hydzik,et al. Fetal death associated with the use of 3,4-MDPHP and α-PHP , 2018, Clinical toxicology.
[34] Markus Müller,et al. Processing strategies and software solutions for data‐independent acquisition in mass spectrometry , 2015, Proteomics.
[35] D. Jerrard. "Designer drugs"--a current perspective. , 1990, The Journal of emergency medicine.
[36] G. Janis,et al. Identification of Unique Metabolites of the Designer Opioid Furanyl Fentanyl. , 2017, Journal of analytical toxicology.
[37] Christian Brinch Mollerup,et al. Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition. , 2017, Drug testing and analysis.
[38] R. Dinis-Oliveira. Metabolism and metabolomics of ketamine: a toxicological approach , 2017, Forensic sciences research.
[39] Matt Anderson,et al. European Monitoring Centre for Drugs and Drug Addiction , 2014 .
[40] A. Janowsky,et al. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters , 2018, Psychopharmacology.
[41] John B. Fenn,et al. Electrospray ionization–principles and practice , 1990 .
[42] G. Hanson,et al. Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine. , 1992, Journal of analytical toxicology.